E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Diabetes Mellitus, Type 2 |
Diabete Mellito, tipo 2 |
|
E.1.1.1 | Medical condition in easily understood language |
Type 2 diabetes |
Diabete tipo 2 |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Nutritional and Metabolic Diseases [C18] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10045242 |
E.1.2 | Term | Type II diabetes mellitus |
E.1.2 | System Organ Class | 100000004861 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective is to confirm that treatment with oral semaglutide does not result in an unacceptable increase in cardiovascular risk compared to placebo (rule out 80% excess risk) in subjects with type 2 diabetes at high risk of cardiovascular events |
L’obiettivo primario è confermare che il trattamento con semaglutide orale non provochi un aumento inaccettabile del rischio cardiovascolare in confronto al trattamento con placebo (esclusione dell’ 80% di eccesso di rischio), in soggetti affetti da diabete tipo 2 ad alto rischio di eventi cardiovascolari. |
|
E.2.2 | Secondary objectives of the trial |
The secondary objectives are to compare the efficacy and safety of oral semaglutide versus placebo in subjects with type 2 diabetes at high risk of cardiovascular events |
Gli obiettivi secondari consistono nel mettere a confronto l’efficacia e la sicurezza di semaglutide orale rispetto al placebo in soggetti affetti da diabete tipo 2 ad alto rischio di eventi cardiovascolari. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Male or female diagnosed with type 2 diabetes
2. Age ≥ 50 years at screening and presence of cardiovascular disease, or age ≥ 60 years at screening and presence of at least one cardiovascular risk factor
|
1. Soggetti di sesso maschile o femminile a cui è stato diagnosticato il diabete tipo 2. 2. Età ≥ 50 anni allo screening e di una patologia cardiovascolare, oppure età ≥ 60 anni allo screening e presenza di almeno un fattore di rischio cardiovascolare.
|
|
E.4 | Principal exclusion criteria |
1. Current or previous (within 90 days prior to screening) treatment with any GLP-1 receptor agonist, DPP-4 inhibitor or pramlintide
2. Family or personal history of multiple endocrine neoplasia type 2 (MEN 2) or medullary thyroid carcinoma (MTC)
3. History of pancreatitis (acute or chronic)
4. History of major surgical procedures involving the stomach potentially affecting absorption of trial product (e.g. subtotal and total gastrectomy, sleeve gastrectomy, gastric bypass surgery)
5. Subjects presently classified as being in New York Heart Association (NYHA) Class IV heart failure
6. Planned coronary, carotid or peripheral artery revascularisation known on the day of screening
7. Any of the following: myocardial infarction, stroke or hospitalisation for unstable angina or transient ischaemic attack within the past 60 days prior to screening
8. Chronic or intermittent hemodialysis or peritoneal dialysis or severe renal impairment (corresponding to eGFR <30 mL/min/1.73 m^2)
9. History or presence of malignant neoplasms within the last 5 years (except basal and squamous cell skin cancer and carcinoma in situ)
|
1. Trattamento attuale o pregresso (entro i 90 giorni precedenti lo screening) con qualsiasi agonista del recettore GLP-1, inibitore di DPP-4 o pramlintide. 2. Storia familiare o personale di neoplasia endocrina multipla di tipo 2 (Multiple Endocrine Neoplasia Type 2, MEN 2) o carcinoma midollare della tiroide (Medullary Thyroids Carcinoma, MTC). 3. Storia di pancreatite (acuta o cronica). 4. Storia di interventi chirurgici maggiori che coinvolgono lo stomaco e che influiscono potenzialmente sull’assorbimento del prodotto sperimentale (ad es. gastrectomia parziale o totale, gastrectomia a manica, intervento di bypass gastrico). 5. Soggetti attualmente classificati con insufficienza cardiaca di Classe IV dalla New York Heart Association (NYHA). 6. Pianificazione di procedure di rivascolarizzazione arteriosa periferica, carotidea o coronarica, note il giorno dello screening. 7. Uno qualsiasi dei seguenti eventi: infarto del miocardio, ictus o ricovero in ospedale per angina instabile o per attacco ischemico transitorio nei 60 giorni precedenti lo screening. 8. Emodialisi continua o intermittente, dialisi peritoneale o grave insufficienza renale (corrispondente a eGFR <30 ml/min/1,73 m2). 9. Diagnosi o storia medica di neoplasie maligne negli ultimi 5 anni (fatta eccezione per il carcinoma basale e squamoso e per il carcinoma in situ). |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary endpoint is time from randomisation to first occurrence of a major adverse cardiovascular event (MACE) composite endpoint consisting of: cardiovascular death, non-fatal myocardial infarction or non-fatal stroke. |
L’endpoint primario è l’intervallo di tempo che va dalla randomizzazione al verificarsi del primo evento avverso cardiovascolare maggiore (MACE), endpoint composito costituito da: morte cardiovascolare, infarto del miocardio non fatale o ictus non fatale. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Maximum treatment duration is dependent on event rates and is estimated to be no longer than 19 months. |
La durata massima del trattamento dipende dal tasso di eventi ed è stata stimata non superiore ai 19 mesi. |
|
E.5.2 | Secondary end point(s) |
1. Time from randomisation to first occurrence of an expanded composite cardiovascular endpoint consisting of: cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, unstable angina requiring hospitalisation or hospitalisation for heart failure 2. Time from randomisation to first occurrence of each of the individual components in the expanded composite cardiovascular endpoint 3. Time from randomisation to first occurrence of a composite endpoint consisting of: all-cause death, non-fatal myocardial infarction or nonfatal stroke |
1 - • L’intervallo di tempo dalla randomizzazione al verificarsi del primo endpoint cardiovascolare composito che include: morte cardiovascolare, infarto del miocardio non fatale o ictus non fatale, angina instabile che richieda il ricovero o ricovero per insufficienza cardiaca 2 - • L’intervallo di tempo dalla randomizzazione al primo verificarsi di ciascuno dei componenti individuali dell’endpoint cardiovascolare composito esteso 3 - • L’intervallo di tempo dalla randomizzazione al primo verificarsi di un endpoint composito costituito da: qualsiasi causa di decesso, infarto del miocardio non fatale o ictus non fatale |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
All endpoints: Maximum treatment duration is dependent on event rates and is estimated to be no longer than 19 months |
Per tutti gli Ednpoints: La durata massima del trattamento dipende dal tasso di eventi ed è stata stimata non superiore ai 19 mesi |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 7 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 55 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Algeria |
Argentina |
Brazil |
Canada |
European Union |
India |
Israel |
Malaysia |
Mexico |
South Africa |
Taiwan |
Thailand |
Turkey |
United States |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 9 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 9 |
E.8.9.2 | In all countries concerned by the trial days | 0 |